<DOC>
	<DOC>NCT02174900</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with artemether-lumefantrine in G6PD deficient males with an asymptomatic P. falciparum malaria infection.</brief_summary>
	<brief_title>Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>1. Male gender 2. Age ≥18 years and ≤45 years 3. BMI ≥16 4. P. falciparum parasitaemia at any density 5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control group receiving AL only (N=50) 6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20) 7. Informed consent by participant 1. Enrolled in another clinical trial 2. Fever &gt;37.5°C (tympanic) or history of fever in the last 24 hours 3. Evidence of severe illness / danger signs or active infection other than malaria 4. Known allergy to study medications 5. Hb &lt;11 g/dL 6. Antimalarials taken within the last 2 weeks 7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days 8. Nonfalciparum malaria coinfection 9. Current use of tuberculosis or antiretroviral medication, sulphonamides, dapsone, nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue phenazopyridine and cotrimoxazole. 10. History of severe chronic illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>G6PD deficiency</keyword>
	<keyword>safety</keyword>
	<keyword>transmission</keyword>
</DOC>